Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies

Journal of Hepatology

Volumn 40, Issue 6, 2004, Pages 1000-1007

  Zemel, Romy ^a   Berdichevsky, Yevgeny ^a   Bachmatov, Larisa ^a   Benhar, Itai ^a   Tur Kaspa, Ran ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Hepatitis C virus; Intrabodies; Liver diseases; Serine protease; Tumorigenicity

Indexed keywords

HEPATITIS C ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY ISOLATION; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; LIVER CARCINOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRUS CELL TRANSFORMATION; VIRUS INHIBITION;

AMINO ACID SEQUENCE; ANIMALS; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CLONING, MOLECULAR; HEPACIVIRUS; MOLECULAR SEQUENCE DATA; PLASMIDS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 2442691367     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(04)00099-6     Document Type: Article

References (41)

1. Brechot C. Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci. 41:1996;6S-21S
2. Purcell R. The hepatitis C virus: overview. Hepatology. 26:1997;11S-14S
3. Bradley D.W. Hepatitis viruses: their role in human cancer. Proc Assoc Am Physicians. 111:1999;588-593
4. Okuda K. Hepatocellular carcinoma. J Hepatol. 32:2000;225-237
5. Bartenschlager R. Candidate targets for hepatitis C virus-specific antiviral therapy. Intervirology. 40:1997;378-393
6. Pawlotsky J.M. Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha. J Viral Hepat. 6:1999;47-48
7. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965
8. Clarke B.E. New drugs for hepatitis C virus (HCV). Baillieres Best Pract Res Clin Gastroenterol. 14:2000;293-305
9. Pawlotsky J.M. Hepatitis C virus resistance to antiviral therapy. Hepatology. 32:2000;889-896
10. Failla C., Tomei L., De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol. 68:1994;3753-3760
11. Borowski P., Kuhl R., Laufs R., Schulze zur Wiesch J., Heiland M. Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. J Clin Virol. 13:1999;61-69
12. Borowski P., Heiland M., Feucht H., Laufs R. Characterisation of non-structural protein 3 of hepatitis C virus as modulator of protein phosphorylation mediated by PKA and PKC: evidences for action on the level of substrate and enzyme. Arch Virol. 144:1999;687-701
13. Ishido S., Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. Fed Eur Biochem Sci Lett. 438:1998;258-262
14. Zemel R., Gerechet S., Greif H., Bachmatove L., Birk Y., Golan-Goldhirsh A., et al. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat. 8:2001;96-102
15. Baltimore D. Gene therapy. Intracellular immunization. Nature. 335:1988;395-396
16. Marasco W.A. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4:1997;11-15
17. Beerli R.R., Wels W., Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem. 269:1994;23931-23936
18. Beerli R.R., Wels W., Hynes N.E. Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies. Breast Cancer Res Treat. 38:1996;11-17
19. Deshane J., Siegal G.P., Alvarez R.D., Wang M.H., Feng M., Cabrera G., et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest. 96:1995;2980-2989
20. Cattaneo A., Biocca S. The selection of intracellular antibodies. Trends Biotechnol. 17:1999;115-121
21. Hoogenboom H.R., de Bruine A.P., Hufton S.E., Hoet R.M., Arends J.W., Roovers R.C. Antibody phage display technology and its applications. Immunotechnology. 4:1998;1-20
22. Benhar I. Biotechnological applications of phage and cell display. Biotechnol Adv. 19:2001;1-33
23. Benhar I., Azriel R., Nahary L., Shaky S., Berdichevsky Y., Tamarkin A., et al. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA′ fusions on live bacteria. J Mol Biol. 301:2000;893-904
24. Berdichevsky Y., Zemel R., Bachmatov L., Abramovich A., Koren R., Sathiyamoorthy P., et al. A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods. 107:2003;245-255
25. Berdichevsky Y., Ben-Zeev E., Lamed R., Benhar I. Phage display of a cellulose binding domain from Clostridium thermocellum and its application as a tool for antibody engineering. J Immunol Methods. 228:1999;151-162
26. Bach H., Mazor Y., Shaky S., Shoham-Lev A., Berdichevsky Y., Gutnick D.L., et al. Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies. J Mol Biol. 312:2001;79-93
27. Brizzard B.L., Chubet R.G., Vizard D.L. Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. Biotechniques. 16:1994;730-735
28. Harlow E., Lane D. Using antibodies: a laboratory manual. 1999;Cold Spring Harbor Laboratory Press, New York
29. Gieni R.S., Li Y., HayGlass K.T. Comparison of [3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods. 187:1995;85-93
30. Marasco W.A. Intrabodies as antiviral agents. Curr Top Microbiol Immunol. 260:2001;247-270
31. Kwong A.D., Kim J.L., Rao G., Lipovsek D., Raybuck S.A. Hepatitis C virus NS3/4A protease. Antiviral Res. 40:1998;1-18
32. Kasai N., Tsumoto K., Niwa S., Misawa S., Ueno T., Hayashi H., et al. Inhibition of the hepatitis C virus NS3 protease activity by Fv fragment of antibody 8D4. Biochem Biophys Res Commun. 281:2001;416-424
33. Dimasi N., Pasquo A., Martin F., Di Marco S., Steinkuhler C., Cortese R., et al. Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein. Protein Eng. 11:1998;1257-1265
34. Harada T., Kim D.W., Sagawa K., Suzuki T., Takahashi K., Saito I., et al. Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J Gen Virol. 76:1995;1215-1221
35. Krawczynski K., Beach M.J., Bradley D.W., Kuo G., di Bisceglie A.M., Houghton M., et al. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. Gastroenterology. 103:1992;622-629
36. Sansonno D., Dammacco F. Hepatitis C virus c100 antigen in liver tissue from patients with acute and chronic infection. Hepatology. 18:1993;240-245
37. Wolk B., Sansonno D., Krausslich H.G., Dammacco F., Rice C.M., Blum H.E., et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol. 74:2000;2293-2304
38. Moradpour D., Bieck E., Hugle T., Wels W., Wu J.Z., Hong Z., et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 277:2002;593-601
39. Heintges T., zu Putlitz J., Wands J.R. Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein. Biochem Biophys Res Commun. 263:1999;410-418
40. Tessmann K., Erhardt A., Haussinger D., Heintges T. Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase. J Virol Methods. 103:2002;75-88
41. Kabat E.A., National Institutes of Health US. Sequences of proteins of immunological interest. 1991;US Department of Health and Human Services Public Health Service National Institutes of Health, Bethesda, MD